about
Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancersSynthesis and NMR structure of p41icf, a potent inhibitor of human cathepsin LFragment-based identification of a locus in the Sec7 domain of Arno for the design of protein-protein interaction inhibitorsThyroid peroxidase autoantibodies obtained from random single chain FV libraries contain the same heavy/light chain combinations as occur in vivo.Generation of llama single-domain antibodies against methotrexate, a prototypical hapten.A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: Immunogenicity and efficacy.Antibody targeting of claudin-1 as a potential colorectal cancer therapy.The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.Intracellular distribution of viral gene products regulates a complex mechanism of cauliflower mosaic virus acquisition by its aphid vector.Functional specific binding of testosterone to Schistosoma haematobium 28-kilodalton glutathione S-transferase.Computational and biophysical approaches to protein-protein interaction inhibition of Plasmodium falciparum AMA1/RON2 complex.A method to confer Protein L binding ability to any antibody fragment.Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.Characterization of monoclonal antibodies against Escherichia coli core RNA polymerase.Developments in SPR Fragment Screening.Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies.Oligomeric-induced activity by thienyl pyrimidine compounds traps prion infectivity.Cyclophilin A as negative regulator of apoptosis by sequestering cytochrome c.Llama single-domain antibodies directed against nonconventional epitopes of tumor-associated carcinoembryonic antigen absent from nonspecific cross-reacting antigen.Biological activities on T lymphocytes of a baculovirus-expressed chimeric recombinant IgG1 antibody with specificity for the CDR3-like loop on the D1 domain of the CD4 molecule.Changes in the dimeric state of neuronal nitric oxide synthase affect the kinetics of secretagogue-induced insulin response.Enhancement of radiation therapy by tumor necrosis factor alpha in human colon cancer using a bispecific antibody.Protein-disulfide isomerase (PDI) in FRTL5 cells. pH-dependent thyroglobulin/PDI interactions determine a novel PDI function in the post-endoplasmic reticulum of thyrocytes.Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity.Insight into invertebrate defensin mechanism of action: oyster defensins inhibit peptidoglycan biosynthesis by binding to lipid II.Kinetics of interaction between ADP-ribosylation factor-1 (Arf1) and the Sec7 domain of Arno guanine nucleotide exchange factor, modulation by allosteric factors, and the uncompetitive inhibitor brefeldin A.Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.Precise characterization of the epitope recognized by a monoclonal antibody against Escherichia coli RNA polymerase.Increment in Drug Loading on an Antibody-Drug Conjugate Increases Its Binding to the Human Neonatal Fc Receptor in Vitro.The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages.Thrombospondin-1 (TSP-1), a new bone morphogenetic protein-2 and -4 (BMP-2/4) antagonist identified in pituitary cells.Atomic Force Microscopy Study of the Topography and Nanomechanics of Casein Micelles Captured by an Antibody.IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding.Nanofluidic Fluorescence Microscopy (NFM) for real-time monitoring of protein binding kinetics and affinity studies.Casein interactions studied by the surface plasmon resonance technique.Structure-activity relationships of phenyl-furanyl-rhodanines as inhibitors of RNA polymerase with antibacterial activity on biofilms.Cyclophilin A enables specific HIV-1 Tat palmitoylation and accumulation in uninfected cells.PIP30/FAM192A is a novel regulator of the nuclear proteasome activator PA28γImmunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodiesTargeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer
P50
Q24792155-4C514800-89CC-4DFE-8002-BBA1969DAE8DQ27640432-401494CF-70F5-4CB4-A4FD-A46753545AB7Q27687079-5817021A-F441-4C94-B4E4-D2D754751E8BQ31018845-A1BBB615-E2E6-4CF7-ACB9-00948752DC64Q33258925-0436E12C-6633-4F25-A047-0C8350F68858Q33467203-6CACD0B4-F642-4847-8127-D57D4260E17CQ33850900-997B34B4-2F26-4641-8C56-A61DCC692F46Q33911286-A4F33BA1-D22A-4906-9398-53E7D3E0C992Q34013502-309975D9-AC6F-495F-B8FD-C59D0D454759Q34118588-701C6E3D-63B5-4EC2-851A-9A11BE961212Q35589799-3BF2A95C-8A8C-48D0-A9E7-A0003F24027AQ35873147-4A7FECF7-5104-48E4-AEE3-250CA5A69FFAQ36670915-8132C52D-31E1-4371-BCD7-768E85DB77F4Q38293414-D94989F2-569D-475C-A631-42268939A767Q38762947-1C7DBE43-B983-4F31-8856-DB779444E962Q38790644-743BC8B6-CE12-40C7-9D10-72B8857AA6A9Q39455005-4E214618-63A3-4D5E-8A79-1927E94421E6Q39742626-1D058A2F-D416-466E-824A-B1F4D252440AQ39837303-32CC59C0-8184-4391-A833-EBB7E6096F91Q40326835-2AFFD899-C2A9-4C3C-98A0-B7290152B771Q40552125-D12BDCF5-1CC6-429F-84EF-D7AB8C9D60C2Q40661845-215A3A26-41FF-4CCA-84F6-E5702416D954Q40906037-F826000B-940E-4218-8980-453CEE5E840AQ41349651-6558664A-8BF0-4DCC-9076-F4B70932E73CQ41810959-E4F1F979-23CA-477F-9996-9CBAF7A88447Q41915041-9C2072F8-3C5F-40DC-9B1D-656397F40784Q42186417-E215FF7B-D90C-4822-914B-C7312F272406Q42651502-08E23D47-0E56-40D5-9668-2C4A50E7E834Q46592291-9DA7D258-6DA6-47A6-8EE0-BB1CE83E804EQ47103062-13D59B6C-30F3-40F2-9B3E-B755D075B72CQ48024041-FB2D0849-9D64-4B15-86AA-899E2624EF6AQ48062107-0AA492F5-0A1A-42E4-B86D-AFC62FFEF35DQ48277947-DA5B48E3-1B5F-4C25-95F7-CB6BAE8BA03AQ51573976-CF5D81E1-E193-4533-8FB0-9D70A44361C2Q51600692-22C391C6-6B79-41C0-B7C4-1B7498F9D2FCQ51795663-F3644691-2941-49B9-9604-53137A615DBCQ55365547-31B8A27B-FDB1-4D55-8609-394BAEE3BADFQ56753804-2CD432A5-A6AF-4258-B51B-22DB1D21B270Q61800299-13A5DDDE-3936-422E-A5C2-167E422131A4Q61849088-2D560794-E5DA-4CD0-A7E8-2D56E74D01BE
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-2049-2909
@en
name
Martine Pugniere
@ast
Martine Pugniere
@en
Martine Pugniere
@es
Martine Pugniere
@nl
type
label
Martine Pugniere
@ast
Martine Pugniere
@en
Martine Pugniere
@es
Martine Pugniere
@nl
prefLabel
Martine Pugniere
@ast
Martine Pugniere
@en
Martine Pugniere
@es
Martine Pugniere
@nl
P106
P31
P496
0000-0002-2049-2909